efavirenz and jtk-303
efavirenz has been researched along with jtk-303 in 16 studies
Research
Studies (16)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Allen, SH; Boros, EE; Ferris, RG; Foster, SA; Fujiwara, T; Gartland, MJ; Garvey, EP; Hazen, RJ; Johns, BA; Kobayashi, M; Koble, CS; Miki, S; Miller, WH; Nakahara, K; Noshi, T; Sato, A; Schaller, LT; Sherrill, RG; Thompson, JB; Underwood, MR; Wakasa-Morimoto, C; Weatherhead, JG; Yoshinaga, T | 1 |
| Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M | 1 |
| Engelman, A; Haim, H; Koh, Y | 1 |
| Brown, KW; Ferris, R; Foster, SA; Fujiwara, T; Garvey, EP; Hazen, RJ; Johns, BA; Kawasuji, T; Kawauchi-Miki, S; Kobayashi, M; Miki, S; Sato, A; Seki, T; Suyama-Kagitani, A; Taishi, T; Underwood, MR; Wakasa-Morimoto, C; Yoshinaga, T | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Mao, TQ; Pannecouque, C; Tang, GF; Wan, ZY | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Pommer, P | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL | 1 |
| Shafer, RW | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J | 1 |
| Alfaro, J; Bogdanov, AA; Bolotin, E; Castillo, G; Gottikh, MB; Gupta, S; Leporati, A | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
Trials
3 trial(s) available for efavirenz and jtk-303
| Article | Year |
|---|---|
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Other Studies
13 other study(ies) available for efavirenz and jtk-303
| Article | Year |
|---|---|
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Topics: Anti-HIV Agents; Cell Line; Cells, Cultured; Drug Resistance, Viral; Drug Synergism; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutation; Naphthyridines; Reverse Transcriptase Inhibitors; Virus Integration; Virus Replication | 2008 |
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication | 2008 |
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
Topics: Adenine; Anti-HIV Agents; Cell Line; HeLa Cells; HIV-1; Humans; Integrase Inhibitors; Organophosphonates; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tenofovir; Zidovudine | 2011 |
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Topics: Anti-HIV Agents; Cell Line; Cell Line, Transformed; Drug Resistance, Viral; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Naphthyridines; T-Lymphocytes; Virus Integration; Virus Replication | 2011 |
Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; Granulocyte Precursor Cells; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Virus Latency | 2015 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Lopinavir; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2017 |
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin | 2018 |
Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Liberation; Drug Resistance, Viral; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Nanoparticles; Polyethylene Glycols; Polylysine; Quinolones; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution | 2019 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |